Guildford, UK – 20 January 2020: On 2 December 2019, Ergomed plc (LSE: ERGO) ("Ergomed" or the "Company"), a company focused on providing specialised services to the pharmaceutical industry, announced the appointment of Lewis Cameron as Chief Operating Officer (COO) and to the Board. Ergomed confirms that, as stated in that announcement, Lewis has today commenced his employment as COO and his appointment to the Board has been effected.
Ergomed confirms that there have been no changes to the disclosures made in the announcement dated 2 December 2019 (RNS number 2883V) regarding Rule 17 of paragraph (g) of Schedule Two of the AIM Rules for Companies in respect of Lewis Cameron's appointment.
About Ergomed plc
Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical trials, post-approval pharmacovigilance and medical information. Ergomed's fast-growing, profitable services business includes a full range of high-quality contract research and clinical trial management (CRO) services under the Ergomed brand together with an industry-leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand, and an internationally recognized specialist expertise in orphan drug development, under the PSR brand. For further information, visit: http://ergomedplc.com.